Genzyme Renagel Kidney Disease Trials Focus On Moderate/Severe Patients
Executive Summary
Genzyme's Renagel development program in chronic kidney disease will initially focus on moderate to severe patients who are under the care of a nephrologist
You may also be interested in...
Genzyme Renagel Margins To Exceed 70% Following Manufacturing Upgrades
Genzyme expects Renagel gross margins to exceed 70% by year-end as a result of manufacturing process upgrades for the phosphate binder
Genzyme Renagel Trial Will Compare Effect On Mortality With Other Agents
Genzyme is studying Renagel's effect on cardiac calcification and mortality to support a comparative claim versus other phosphate binders, Genzyme Senior VP-Corporate Affairs Elliott Hillback told the Bear Stearns "virtual" healthcare conference Sept. 24.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011